Sanner introduces bio-based plastic packaging
Represents the first biopackaging of its kind made of renewable raw materials.
At Pharmapack 2020, Sanner will focus on sustainability and will debut its new Sanner BioBase effervescent tablet packaging. Sanner BioBase is the first biopackaging of its kind made of renewable raw materials.
Sanner BioBase is the first effervescent tablet packaging that consists of more than 90% bio-based material. The biopolymers used consist of various renewable raw materials such as corn, sugar cane or cellulose, which are converted into "green" ethanol. A major advantage of bio-based plastic packaging is its essential independence from fossil raw material deposits and its reduced CO2 footprint. Bio-based plastic packaging has the same properties as conventional packaging solutions. They can also be processed on existing filling lines. From a chemical point of view, Sanner BioBase is almost identical to PE and PP from fossil raw materials.
High-quality and climate-friendly
"Sanner BioBase can be recycled, increases resource efficiency and makes it easier for us to achieve our climate targets," says Ursula Hahn, Head of Product Management at Sanner. Another important argument for customers and consumers is the extended shelf life of the tablets thanks to higher H2O barrier properties. In terms of handling, Sanner BioBase offers consumers a high-quality feel and appearance. The tablet tube can be printed or provided with an IML label.
Sanner BioBase will be commercially available from the second quarter of 2020. The initial tablet tube will have a diameter of 27 millimeters and can be combined with the appropriate desiccant closure. "The solution is currently aimed primarily at food supplement producers," says Ursula Hahn. "Due to the stricter regulations in the pharmaceutical industry, this market will be our next focus".
Sustainability and innovation as part of the corporate DNA
Sanner launched the first desiccant closure for moisture-sensitive tablets 60 years ago and became the market leader for both desiccant and effervescent tablet packaging. "We are continuing this tradition with continuous development work and with the first bio-based effervescent tablet packaging," says Peik-Christian Witte, Director R&D at Sanner. The company’s corporate culture is based on innovation and sustainability: Sanner has been investing in the optimization of its own manufacturing processes for many years. For example, the Bensheim site uses its own combined heat and power generation system. In recent years, the company has been able to significantly reduce CO2 emissions and energy consumption for the production of plastic packaging.
TabTec CR tablet container: child-resistant and senior-friendly
Also on show at Pharmapack: the TabTec CR tablet container, which was launched at the end of 2019 and will also be showcased in the Pharmapack Innovation Gallery. The innovative opening mechanism protects children from accidentally taking painkillers, antidepressants or medical cannabis. The patented Press & Flip closure prevents opening by children's hands. However, it is easy to handle for adults and especially for seniors by pressing and simultaneously folding up the closure. The desiccant integrated into the bottom of the container and the appropriate color selection protect the contents from moisture and light at all times. The integrated pouring assistance ensures hygienic and easy dosing of the drugs.Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance